iZora's CEO identifies a "sweet spot" of three to five high-quality programs. This size is large enough to benefit from risk diversification but small enough to avoid losing focus and stretching resources thin. It provides a concrete framework for balancing ambition with manageable execution and capital requirements.

Upon joining Zevra as CEO, Neil McFarlane's first priority was creating focus. He identified filing the New Drug Application (NDA) for their lead rare disease asset as the single greatest value creator and stopped all other distracting activities to channel the organization's resources toward that one goal.

Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

The lead asset overwhelmingly determines a biotech company's value at IPO or acquisition, with subsequent programs and the platform contributing far less. This means founders must prioritize their most impactful idea as their first program, not a cheaper proof-of-concept, to maximize value creation.

During capital-constrained periods, investors fixate on the single biggest value driver, usually a lead clinical asset. While platforms have value, companies must focus on the asset with the most compelling data to secure funding.

The tough funding environment forced Stellular Bio into "extreme focus" on a single asset. This meant deferring all non-essential R&D, like manufacturing scale-up, to create the most capital-efficient, linear path to an IND filing and first clinical data—the next major value inflection point for investors.